Table 3.
Most relevant studies investigating the role of RT in ependymal tumors. RT = radiation therapy; PFS = progression-free survival; OS = overall survival; NA = not available; pts = patients.
| Study | Trial Design | N° of pts | Median Age (Range) | Grading and Tumor Site | N. of pts Treated with RT | Efficacy |
|---|---|---|---|---|---|---|
| Metellus P et al., 2010 [47] | Retrospective | 114 | 48 (18–82) |
WHO grade II intracranial ependymoma | 35 | 5-year OS: Surgery: 83.4% Surgery plus RT: 92% |
| Nuño M et al., 2016 [16] | Retrospective; USA National Cancer Database | 1055 Grade II 263 Grade III |
44 (31–56) |
WHO grade II/III supratentorial and posterior fossa ependymoma | 662 | RT does not seem to have an impact on overall survival |
| Deng X et al., 2020 [56] | Retrospective; SEER database |
560 Grade II 163 Grade III |
Range (18–68) |
Intracranial WHO grade II/III ependymoma | 422 | RT does not seem to have an impact on overall survival |
| Prabhu RS, et al., 2020 [57] | Retrospective; SEER database | 1787 | 45–50 (37–62) |
WHO grade II/III ependymoma | 856 | 3- and 5-year OS with adjuvant RT was 83.4% and 79.3% versus 86.4% and 81.8% with observation. |
| Woo Wee et al., 2020 [58] | Retrospective; Multicenter retrospective |
172 | NA | WHO grade II/III ependymoma | 110 | 5- and 10-year OS rates were 76.6%/71.0%, respectively. PORT significantly elevated the rates of PFS (p = 0.002), and OS (p = 0.043) |